HZNP / Why Is Horizon Therapeutics (HZNP) Down 9% Since Last Earnings Report?

The Federal Trade Commission suspends its ongoing lawsuit to block Horizon's (HZNP) acquisition by Amgen until Sep 18, 2023. The company's stock rises more_horizontal

Horizon Therapeutics (HZNP) shares jumped more than 5.5% in early trading Monday after the FTC said it would suspend its challenge to Amgen's (AMGN) a more_horizontal

Horizon (HZNP) reports better-than-expected second-quarter results, beating both earnings and sales estimates, with the top-line key contributors bein more_horizontal

The headline numbers for Horizon Therapeutics (HZNP) give insight into how the company performed in the quarter ended June 2023, but it may be worthwh more_horizontal

Horizon Therapeutics (HZNP) came out with quarterly earnings of $1.20 per share, beating the Zacks Consensus Estimate of $1.12 per share. This compare more_horizontal

Horizon (HZNP) fails to meet the primary endpoint in the mid-stage study of evaluating daxdilimab in the treatment of systemic lupus erythematosus. more_horizontal

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? more_horizontal

Amgen's stock has seen a further pullback since it announced an acquisition of Horizon Therapeutics in December. Shares are down by nearly a quarter a more_horizontal